Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets

British Journal of Clinical Pharmacology

Volumn 65, Issue 1, 2008, Pages 110-122

  Tothfalusi, Laszlo ^a   Speidl, Szilvia ^a   Endrenyi, Laszlo ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Absorption rate metrics; Bioequivalence; Carbamazepine; Mixed effect model; PK and PD sensitivities; PK PD relationship

Indexed keywords

CARBAMAZEPINE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FATIGUE; HUMAN; NAUSEA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TABLET;

ANTICONVULSANTS; AREA UNDER CURVE; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM; HUMANS; REFERENCE VALUES; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 37249091680     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02984.x     Document Type: Article

References (39)

1. Besag FM. Is generic prescribing acceptable in epilepsy? Drug Safety 2000 23 : 173 82.
2. Crawford P, Hall WW, Chappell B, Collings J, Stewart A. Generic prescribing for epilepsy. Is it safe? Seizure 1996 5 : 1 5.
3. Neuvonen PJ. Bioavailability and central side effects of different carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol 1985 23 : 226 32.
4. Wolf P, May T, Tiska G, Schreiber G. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations. Arzneimittelforschung 1992 42 : 284 8.
5. Hoppener RJ, Kuyer A, Meijer JW, Hulsman J. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980 21 : 341 50.
6. Riva R, Albani F, Ambrosetto G, Contin M, Cortelli P, Perucca B, Baruzzi A. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia 1984 25 : 476 81.
7. Anttila M, Kahela P, Panelius M, Yrjana T, Tikkanen R, Aaltonen R. Comparative bioavailability of two commercial preparations of carbamazepine tablets. Eur J Clin Pharmacol 1979 15 : 421 5.
8. Pynnonen S, Mantyla R, Iisalo E. Bioavailability of four different pharmaceutical preparations of carbamazepine. Acta Pharmacol Toxicol (Copenh) 1978 43 : 306 10.
9. Meyer MC, Straughn AB, Mhatre RM, Shah VP, Williams RL, Lesko LJ. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res 1998 15 : 1787 91.
10. Olling M, Mensinga TT, Barends DM, Groen C, Lake OA, Meulenbelt J. Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharm Drug Dispos 1999 20 : 19 28.
11. Aldenkamp AP, Rentmeester T, Hulsman J, Majoie M, Doelman J, Diepman L, Schellekens A, Olling M. Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates. Eur J Clin Pharmacol 1998 54 : 185 92.
12. Endrenyi L, Fritsch S, Yan W. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 1991 29 : 394 9.
13. Tothfalusi L, Endrenyi L. Without extrapolation, Cmax/AUC is an effective metric in investigations of bioequivalence. Pharm Res 1995 12 : 937 42.
14. Chen ML. An alternative approach for assessment of rate of absorption in bioequivalence studies. Pharm Res 1992 9 : 1380 5.
15. Endrenyi L, Csizmadia F, Tothfalusi L, Balch AH, Chen ML. The duration of measuring partial AUCs for the assessment of bioequivalence. Pharm Res 1998 15 : 399 404.
16. Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 1995 12 : 1845 55.
17. Karalis V, Macheras P. Pharmacodynamic considerations in bioequivalence assessment: comparison of novel and existing metrics. Eur J Pharm Sci 2003 19 : 45 56.
18. Venables W, Ripley B. Modern Applied Statistics with S. New York : Springer 2002.
19. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. New York : Springer 2000.
20. Hosner D, Lemeshow S. Applied Logistic Regression. New York : Wiley 2000.
21. Emilien G, van Meurs W, Maloteaux JM. The dose-response relationship in phase I clinical trials and beyond: use, meaning, and assessment. Pharmacol Ther 2000 88 : 33 58.
22. Miller R, Ewy W, Corrigan BW, Ouellet D, Hermann D, Kowalski KG, Lockwood P, Koup JR, Donevan S, El-Kattan A, Li CSW, Werth JL, Feltner DE, Lalonde RL. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokin Pharmacodyn 2005 32 : 185 97.
23. Bhattaram VA, Booth BP, Ramchandani RP, Beasley BN, Wang Y, Tandon V, Duan JZ, Baweja RK, Marroum PJ, Uppoor RS, Rahman NA, Sahajwalla CG, Powell JR, Mehta MU, Gobburu JVS. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 2005 7 : E503 12.
24. Dodrill C. Effects of antiepileptic drugs on behavior. In : Frontiers of Clinical Neuroscience, Vol. 12, Epilepsy and Behavior, Devinsky WT. New York : Wiley 1991 : 37 46.
25. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005 5 : 3 14.
26. Benet LZ. Relevance of pharmacokinetics in narrow therapeutic index drugs. Transplant Proc 1999 31 : 1642 4 discussion 1675 84.
27. Miller AD, Krauss GL, Hamzeh FM. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand 2004 109 : 374 7.
28. Pieters MS, van Steveninck AF, Schoemaker RC, Kroon JM, van Gerven JM, Cohen AF. The psychomotor effects of carbamazepine in epileptic patients and healthy volunteers. J Psychopharmacol 2003 17 : 269 72.
29. Arroyo S, Sander JW. Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten. Neurology 1999 53 : 1170 4.
30. Bialer M, Levy RH, Perucca E. Does carbamazepine have a narrow therapeutic plasma concentration range? Ther Drug Monit 1998 20 : 56 9.
31. Bialer M, Yacobi A, Moros D, Levitt B, Houle JM, Munsaka MS. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia 1998 39 : 513 9.
32. Yacobi A, Zlotnick S, Colaizzi JL, Moros D, Masson E, Abolfathi Z, LeBel M, Mehta R, Golander Y, Levitt B. A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine. Clin Pharmacol Ther 1999 65 : 389 94.
33. Guidance for Industry. Bioequivalence Requirements: Critical Dose Drugs. Ottawa : Health Canada 2006. Available at http://www.hc-sc.gc.ca/dhp-mps/ alt_formats/hpfb-dgpsa/pdf/prodpharma/critical_dose_critique_e.pdf Last accessed 27 March 2007.
34. Bioavailability of Oral Dosage Formulations for Systemic Effects. Report C. Ottawa : Expert Advisory Committee on Bioavailability, Health and Welfare Canada 1992. Available at http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/ pdf/prodpharma/biorepc_biorapc_e.pdf Last accessed 27 March 2007.
35. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on the Investigation of Bioavailability and Bioequivalence. CPMP/EWP/QWP/1401/98, London, 26 July 2001. Available at http://www.emea.europa.eu/pdfs/human/ewp/ 140198en.pdf Last accessed 27 March 2007.
36. Bioequivalence and Labelling of Medicinal Products with Regard to Generic Substitution. Updated 17 January 2006. Copenhagen : The Danish Medicines Agency. Available at http://www.dkma.dk/visUKLSArtikel.asp?artikelID=6437 Last accessed 27 March 2007.
37. Tozer TN, Bois FY, Hauck WW, Chen M-L, Williams R. Absorption rate vs. exposure: which is more useful for bioequivalence testing? Pharm Res 1996 13 : 453 6.
38. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence for Orally Administered Drug Products - General Considerations. Revision 1. Rockville, MD. 2003. Available at http://www.fda.gov/cder/guidance/ 5356fnl.pdf Last accessed 27 March 2007.
39. Jaksch P, Kocher A, Neuhauser P, Sarahrudi K, Seweryn J, Wisser W, Klepetko W. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). J Heart Lung Transplant 2005 24 : 1076 80.